29 completed, 13 recruiting, 8 unknown, 5 active not recruiting. 11 Phase 2, 11 Phase 3, 5 Not applicable, 4 Phase 4, 3 Phase 1.
Follow Churg-Strauss Syndrome: new trials by email Literature Review of Churg-Strauss Syndrome trials Research Report on Churg-Strauss Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-09-22 |
| Benralizumab Effectiveness in EGPA Benralizumab 30 mg/ml - Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Recruiting | European EGPA Study Group | 100 | 2026-02-11 | 2026-09-11 | |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study) Mepolizumab 300 mg - Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA) | Completed | European EGPA Study Group | 591 | 2025-09-18 | 2026-09-11 | |
| Effectiveness on Sino-Nasal Symptoms Of Mepolizumab 300 Mepolizumab 300 mg - Sinus Disease, EGPA - Eosinophilic Granulomatosis With Polyangiitis | Completed | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 52 | 2025-09-12 | 2026-05-18 | |
| The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome Blood draw for the laboratory assessment - EGPA - Eosinophilic Granulomatosis With Polyangiitis, HES - Hypereosinophilic Syndrome | Not applicable | Recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 60 | 2025-06-01 | 2025-12-10 |
| A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases Benralizumab - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES) | Phase 3 | Recruiting | AstraZeneca | 14 | 2025-04-17 | 2026-09-18 |
| Eosinophil Subpopulations in Eosinophilic-associated Diseases Eosinophilic Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Not yet recruiting | University of Florence | 160 | 2025-04-01 | 2025-04-04 | |
| Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications Asthma | Completed | GlaxoSmithKline | 107032 | 2024-07-01 | 2026-06-01 | |
| Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis Tezepelumab, Placebo - EGPA - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 | Active not recruiting | Imperial College London | 42 | 2024-05-15 | 2026-04-29 |
| The Epigenomic Signature of Eosinophilic Granulomatosis With Polyangiitis Eosinophilic Granulomatosis With Polyangiitis | Unknown | Meyer Children's Hospital IRCCS | 300 | 2024-04-01 | 2024-02-23 | |
| Ocular Manifestations of Granulomatosis With Polyangiitis. Optical coherence tomography angiography - GPA, Vasculitis | Recruiting | Military Institute od Medicine National Research Institute | 70 | 2024-03-01 | 2026-06-24 | |
| eGPA and Local Inflammation Within the Ear, Nose and Throat Area laboratory experiments before and after mepolizumab treatment - EGPA - Eosinophilic Granulomatosis With Polyangiitis | Recruiting | University Medical Center Groningen | 150 | 2024-02-14 | 2024-03-07 | |
| Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis NS-229, Placebo - Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome | Phase 2 | Active not recruiting | NS Pharma, Inc. | 45 | 2023-12-20 | 2026-05-26 |
| A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） SHR-1703, Mepolizumab Injection - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 166 | 2023-11-16 | 2025-12-04 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Depemokimab, Mepolizumab, Placebo matching mepolizumab - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Active not recruiting | GlaxoSmithKline | 163 | 2022-07-14 | 2026-07-08 |
| Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Mepolizumab, cyclophosphamide/azathioprine, Placebo - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 102 | 2022-05-30 | 2026-10-01 |
| FASENRA Regulatory Postmarketing Surveillance in Korea Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis) | Completed | AstraZeneca | 51 | 2022-03-11 | 2026-02-06 | |
| Hydroxychloroquine in ANCA Vasculitis Evaluation Hydroxychloroquine, Placebo - ANCA Associated Vasculitis, Microscopic Polyangiitis | Phase 4 | Terminated | Guy's and St Thomas' NHS Foundation Trust | 43 | 2020-12-17 | 2026-04-29 |
Showing 20 of 61. Sign in to see all of them.
Microscopic Polyangiitis (26) · Granulomatosis with Polyangiitis (25) · Vasculitis (17) · Polyarteritis Nodosa (16) · Takayasu Arteritis (12) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (10) · Giant Cell Arteritis (10) · IgA Vasculitis (8) · Behcet Syndrome (6) · Vasculitis, Central Nervous System (6) · Hypereosinophilic Syndrome (5) · Asthma (4) · Pulmonary Eosinophilia (4) · Systemic Vasculitis (4)
Autoimmune Diseases (61) · Cardiovascular Diseases (61) · Granuloma (61) · Hemic and Lymphatic Diseases (61) · Lymphatic Diseases (61) · Lymphoproliferative Disorders (61) · Skin Diseases (61) · Skin and Connective Tissue Diseases (61) · Vascular Diseases (61) · Immune System Diseases (60) · Skin Diseases, Vascular (60) · Systemic Vasculitis (57) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (51) · Vasculitis (44) · Lung Diseases (32)
mepolizumab (13) · Cyclophosphamide (6) · Azathioprine (5) · Rituximab (4) · benralizumab (4) · Prednisone (3) · Blood Specimen Collection (2) · Methotrexate (2) · Methylprednisolone (2) · Abatacept (1) · Adrenal Cortex Hormones (1) · Antilymphocyte Serum (1) · Cyclosporine (1) · Filgrastim (1) · Flow Cytometry (1)
University of Pennsylvania (7) · Assistance Publique - Hôpitaux de Paris (6) · GlaxoSmithKline (6) · AstraZeneca (4) · University of South Florida (4) · Charite University, Berlin, Germany (2) · European EGPA Study Group (2) · Imperial College London (2) · University of Oxford (2) · Alpine Immune Sciences, Inc. (1) · Azienda Ospedaliero Universitaria di Cagliari (1) · Brigham and Women's Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · Christian Pagnoux (1) · Fairview University Medical Center (1)
United States (26) · United Kingdom (16) · Canada (15) · France (15) · Italy (13) · Germany (12) · Japan (8) · Belgium (5) · Netherlands (5) · Poland (5) · South Korea (5) · Austria (4) · India (4) · Israel (4) · Spain (4)
Peter A Merkel, MD, MPH (5) · Peter A. Merkel, MD, MPH (4) · Amanda M. Terry, MA (3) · Megan Clowse, MD, MPH (2) · Michael Wechsler, MD (2) · Peter C. Grayson, MD (2) · Peter Merkel, MD, MPH (2) · Adrian Schreiber, PD Dr. med. (1) · Alan Salama (1) · Anoop J Chauhan, PhD FRCP (1) · Antoine Sreih, MD (1) · Arne Slungaard (1) · Augusto Vaglio, MD, PhD (1) · Benjamin Terrier (1)
PMID 28514601, PMID 31719529, PMID 33001543, PMID 34347947, PMID 35612893, PMID 35850947, PMID 37161084, PMID 38251561, PMID 38393328, PMID 18240234, PMID 21325353, PMID 2202307, PMID 23590801, PMID 25153486, PMID 25693055, PMID 27940595, PMID 28678392, PMID 29016646, PMID 31056661, PMID 32638567, PMID 33011303, PMID 33065367, PMID 33164993, PMID 33718405, PMID 35106968, PMID 36874269, PMID 36927642, PMID 37024906, PMID 37334358, PMID 37457743, PMID 37550002, PMID 38231590, PMID 38825350, PMID 38825354, PMID 40008472, PMID 40147217, PMID 40720835, PMID 40977418, PMID 42321206
2023 (3), U54AR057319 (3), 2016 (2), 2014 (1), 2018 (1), 2019 (1), UL1RR024150 (1)